Liquid Biopsy Market to Grow at a CAGR of 21.7% by 2026 FMI | Page 4

Report
Description
Report Description
By disease indication, lung cancer segment is expected to dominate the market, in terms
of revenues. By end user, cancer institutes are estimated to represent a revenue share of
around 38% -- significantly higher compared to other end-use segments, such as
hospitals, academic institutes, and diagnostic centres.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1396
Some of the key players in the global liquid biopsy market include Genomic Health, Inc.,
Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems,
Pathway Genomics Corporation, and Sysmex Corporation. A majority of key companies
are concentrating on mergers, acquisitions, and partnerships; while most of them are
prioritising innovative diagnostics and technological upgrades for better penetration in
developing regional markets.

Long term outlook: The global liquid biopsy market is projected to expand at a CAGR of
21.7% by 2026 end, reaching a value of US$ 2.89 Bn.